12 Month Price Forecast For CATX
Distance to CATX Price Forecasts
CATX Price Momentum
๐ค Considering Perspective Therapeutics (CATX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 10, 2025 2:18 PM UTC
CATX Analyst Ratings & Price Targets
Based on our analysis of 10 Wall Street analysts, CATX has a consensus that is bullish. The median price target is $16.00, with forecasts ranging from $6.00 to $21.00. Currently, there are 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With CATX currently trading at $3.31, the median price forecast suggests a 383.4% upside. The most optimistic forecast comes from Nicole Germino at Truist Securities, projecting a 534.4% upside, while Alec Stranahan at B of A Securities provides the most conservative target, suggesting a 81.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CATX Analyst Consensus
CATX Price Target Range
Latest CATX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CATX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 14, 2025 | RBC Capital | Gregory Renza | Outperform | Reiterates | $16.00 |
Nov 25, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $16.00 |
Nov 25, 2024 | B of A Securities | Alec Stranahan | Neutral | Downgrade | $6.00 |
Nov 22, 2024 | Oppenheimer | Jeff Jones | Outperform | Maintains | $16.00 |
Oct 24, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $20.00 |
Oct 24, 2024 | UBS | David Dai | Buy | Initiates | $20.00 |
Oct 11, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $22.00 |
Oct 1, 2024 | Wedbush | David Nierengarten | Outperform | Initiates | $25.00 |
Sep 25, 2024 | Truist Securities | Nicole Germino | Buy | Initiates | $21.00 |
Sep 10, 2024 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $0.00 |
Sep 9, 2024 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $0.00 |
Sep 6, 2024 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $0.00 |
Sep 3, 2024 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $0.00 |
Aug 16, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $27.00 |
Aug 13, 2024 | Oppenheimer | Jeff Jones | Outperform | Maintains | $17.00 |
Jul 25, 2024 | B of A Securities | Alec Stranahan | Buy | Initiates | $24.00 |
Jun 25, 2024 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $0.00 |
Jun 20, 2024 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $0.00 |
Jun 18, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $0.00 |
Jun 18, 2024 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $0.00 |
Stocks Similar to Perspective Therapeutics, Inc. Common Stock
The following stocks are similar to Perspective Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Perspective Therapeutics, Inc. Common Stock (CATX) Financial Data
Perspective Therapeutics, Inc. Common Stock has a market capitalization of $223.71M with a P/E ratio of -1.9x. The company generates $1.56M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +33.7% quarter-over-quarter, while maintaining an operating margin of -5,049.9% and return on equity of -27.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Perspective Therapeutics, Inc. Common Stock (CATX) Company Overview
About Perspective Therapeutics, Inc. Common Stock
Develops precision-targeted alpha therapies for oncology.
The company focuses on developing and commercializing precision-targeted alpha therapies (TAT) to treat various types of cancer, particularly in patients with metastatic disease. Its primary revenue potential lies in the successful development and commercialization of its drug candidates, which are currently in clinical trials. Collaborations, such as the one with Bristol Myers Squibb, may also enhance its research capabilities and market reach.
Founded in 1998 and headquartered in Seattle, Washington, the company previously operated under the name Isoray, Inc. It is actively engaged in clinical trials for innovative treatments targeting specific cancer markers, aiming to provide effective options for patients who have not responded to existing therapies.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
116
CEO
Mr. Johan M. Spoor
Country
United States
IPO Year
2005
Website
www.perspectivetherapeutics.comPerspective Therapeutics, Inc. Common Stock (CATX) Latest News & Analysis
Perspective Therapeutics, Inc. will have its senior leadership team available for one-on-one meetings with investors at upcoming conferences, enhancing investor engagement opportunities.
Perspective Therapeutics' participation in investor conferences signals engagement with the investment community, potentially boosting investor confidence and interest in the company's growth and innovations.
Perspective Therapeutics reported positive interim results from its Phase 1/2a trial of [212Pb]VMT-ฮฑ-NET, showing a favorable safety profile and objective responses in some patients.
Positive interim results from the Phase 1/2a study of [212Pb]VMT-ฮฑ-NET, showing safety and early objective responses, could enhance investor confidence and drive stock value for Perspective Therapeutics.
Perspective Therapeutics, Inc. appointed Juan Graham as CFO effective January 6, 2025. Jonathan Hunt remains with the company as Chief Accounting Officer.
Leadership changes, especially in key financial positions, can signal a shift in company strategy or stability, impacting investor confidence and stock performance.
Perspective Therapeutics is developing radiopharmaceuticals for oncology, focusing on theranostics to target tumors while minimizing healthy tissue damage. Their candidates VMT01 and VMT-ฮฑ-NET are in Phase 1/2 trials, with VMT01 receiving Fast Track Designation.
Perspective Therapeutics' theranostics approach could revolutionize cancer treatment, enhancing efficacy and reducing side effects. Promising trials and Fast Track Designation could drive future growth.
Perspective Therapeutics' alpha emitter PRRT demonstrates potential in early trials for GEP-NETs and melanoma, with manageable toxicity. The company has a strong cash position to support ongoing research.
Perspective Therapeutics' promising trial results for PRRT may signal a breakthrough in cancer treatment, enhancing long-term research viability amid market skepticism and potential valuation recovery.
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced its senior leadership will attend upcoming investor conferences for one-on-one meetings with investors.
Perspective Therapeutics' participation in investor conferences signals potential growth and transparency, attracting investor interest and possibly impacting stock performance.
Frequently Asked Questions About CATX Stock
What is Perspective Therapeutics, Inc. Common Stock's (CATX) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Perspective Therapeutics, Inc. Common Stock (CATX) has a median price target of $16.00. The highest price target is $21.00 and the lowest is $6.00.
Is CATX stock a good investment in 2025?
According to current analyst ratings, CATX has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CATX stock?
Wall Street analysts predict CATX stock could reach $16.00 in the next 12 months. This represents a 383.4% increase from the current price of $3.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Perspective Therapeutics, Inc. Common Stock's business model?
The company focuses on developing and commercializing precision-targeted alpha therapies (TAT) to treat various types of cancer, particularly in patients with metastatic disease. Its primary revenue potential lies in the successful development and commercialization of its drug candidates, which are currently in clinical trials. Collaborations, such as the one with Bristol Myers Squibb, may also enhance its research capabilities and market reach.
What is the highest forecasted price for CATX Perspective Therapeutics, Inc. Common Stock?
The highest price target for CATX is $21.00 from Nicole Germino at Truist Securities, which represents a 534.4% increase from the current price of $3.31.
What is the lowest forecasted price for CATX Perspective Therapeutics, Inc. Common Stock?
The lowest price target for CATX is $6.00 from Alec Stranahan at B of A Securities, which represents a 81.3% increase from the current price of $3.31.
What is the overall CATX consensus from analysts for Perspective Therapeutics, Inc. Common Stock?
The overall analyst consensus for CATX is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are CATX stock price projections?
Stock price projections, including those for Perspective Therapeutics, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.